Frontiers in Oncology 2020 February 21 [Link] de Gooijer CJ, Borm FJ, Scherpereel A, Baas P Abstract The only registered systemic treatment for malignant pleural mesothelioma (MPM) is platinum based chemotherapy combined with pemetrexed, with or without bevacizumab. Immunotherapy did seem active in small phase II trials. In this review, we will highlight the most […]
March 24, 2020
Cancers 2020 February 27 [Link] Trempolec N, Doix B, Degavre C, Brusa D, Bouzin C, Riant O, Feron O Abstract The potential of dendritic cell (DC)-based immunotherapy to treat cancer is, nowadays, well documented. Still, the clinical success of immune checkpoint inhibitors has dampened the interest in anticancer DC vaccination. For highly life-threatening tumors that […]
March 17, 2020
Annals of Oncology 2020 January 16 [Link] Metaxas Y, Früh M, Eboulet EI, Grosso F, Pless M, Zucali PA, Ceresoli GL, Mark M, Schneider M, Maconi A, Perrino M, Biaggi-Rudolf C, Froesch P, Schmid S, Waibel C, Appenzeller C, Rauch D, von Moos R; Swiss Group for Clinical Cancer Research (SAKK). Abstract BACKGROUND: Systemic second- […]
March 4, 2020
Frontiers in Immunology 2020 January 10 [Link] Hope JL, Spantidea PI, Kiernan CH, Stairiker CJ, Rijsbergen LC, van Meurs M, Brouwers-Haspels I, Mueller YM, Nelson DJ, Bradley LM, Aerts JGJV, Katsikis PD Abstract The immune system, and in particular, cytotoxic CD8+ T cells (CTLs), plays a vital part in the prevention and elimination of tumors. In […]
February 5, 2020
Journal of Thoracic Oncology 2020 January 13 [Link] Delaunay T, Achard C, Boisgerault N, Grard M, Petithomme T, Chatelain C, Dutoit S, Blanquart C, Royer PJ, Minvielle S, Quetel L, Meiller C, Jean D, Fradin D, Bennouna J, Magnan A, Cellerin L, Tangy F, Grégoire M, Fonteneau JF Abstract Oncolytic immunotherapy is based on the […]
January 27, 2020
Oncotarget 2019 November 5 [Link] Donnenberg AD, Luketich JD, Donnenberg VS Abstract INTRODUCTION: We compared the secretome of metastatic (non-small cell lung cancer (NSCLC)) and primary (mesothelioma) malignant pleural effusions, benign effusions and the published plasma profile of patients receiving chimeric antigen receptor T cells (CAR-T), to determine factors unique to neoplasia in pleural effusion […]
November 29, 2019
International Journal of Molecular Sciences 2019 August 26 [Link] Marcq E, Audenaerde JRV, Waele J, Jacobs J, Loenhout JV, Cavents G, Pauwels P, Meerbeeck JPV, Smits EL Abstract In light of the promising results of immune checkpoint blockade (ICPB) in malignant pleural mesothelioma (MPM), we investigated the effect of different chemotherapeutic agents on the expression […]
September 13, 2019
Oncoimmunology 2019 April 17 [Link] Bertino P, Premeaux TA, Fujita T, Haun BK, Marciel MP, Hoffmann FW, Garcia A, Yiang H, Pastorino S, Carbone M, Niki T, Berestecky J, Hoffmann PR, Ndhlovu LC Abstract Galectin-9 has emerged as a promising biological target for cancer immunotherapy due to its role as a regulator of macrophage and […]
August 29, 2019
Cureus 2019 February 20 [Link] Barsky AR, Cengel KA, Katz SI, Sterman DH, Simone CB Abstract Malignant pleural mesothelioma (MPM) is a highly aggressive disease, with few, if any, curative interventions. While there is growing interest in using immunotherapy and immuno-gene therapy to treat MPM, very limited data currently exist for combining these modalities with […]
May 15, 2019
Clinical Lung Cancer 2018 May 9 [Link] Fujimoto N, Aoe K, Kozuki T, Oze I, Kato K, Kishimoto T, Hotta K
June 8, 2018